References
- Molyneux E, Rochford R, Griffin B, et al. Burkitt lymphoma. Lancet 2012;379:1234–1244.
- God JM, Haque A. Burkitt lymphoma: pathogenesis and immune evasion. J Oncol 2010;2010. pii: 516047. Epub 2010 Oct 5.
- Ferry JA. Burkitt lymphoma: clinicopathologic features and differential diagnosis. Oncologist 2006;11:375–383.
- Hoffman R. Hematology: basic principles and practice. 5th ed. Philadelphia, PA: Churchill Livingstone/Elsevier; 2009. p 1304–1305.
- Liu D, Shimonov J, Primanneni S, et al. t(8;14;18): a 3-way chromosome translocation in two patients with Burkitt lymphoma/leukemia. Mol. Cancer 2007;6:35.
- Smardova J, Grochova D, Fabian P, et al. An unusual p53 mutation detected in Burkitt lymphoma: 30 bp duplication. Oncol Rep 2008;20: 773–778.
- Brady G, MacArthur GJ, Farrell PJ. Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol 2007;60:1397–1402.
- Bellan C, Lazzi S, De Falco G, et al. Burkitt lymphoma: new insights into molecular pathogenesis. J Clin Pathol 2003;56:188–192.
- van den Bosch CA. Is endemic Burkitt lymphoma an alliance between three infections and a tumour promoter? Lancet Oncol 2004;5: 738–746.
- Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008;26:2717–2714.
- Okebe JU, Lasserson TJ, Meremikwu MM, et al. Therapeutic interventions for Burkitt lymphoma in children. Cochrane Database Syst Rev 2006;:CD005198.
- Yustein JT, Dang CV. Biology and treatment of Burkitt lymphoma. Curr Opin Hematol 2007;14:375–381.
- Bible Tradi Chin Med 2nd ed. 1996; 2360.
- Li M, Shen J, Xu B, et al. The Mechanism of laboratory research for xiaoaiping treating SGC-7901 gastric carcinoma cellular strains. J Interven Radiol 2001;10:228–231.
- Hu YJ, Shen XL, Lu HL, et al. Tenacigenin B derivatives reverse p-glycoprotein-mediated multidrug resistance in HepG2/Dox cell. J Nat Prod 2008;71:1049–1051.
- Meng Z, Wu C. Isolation of Tenacigenin B derivatives and their in vitro anti-tumor effects. Strait Pharma J 2009;21:34–37.
- Liang X, Gao G, Zhou X, et al. XiaoAiPing injection inhibited the tumor vascular generation of Lewis lung cancer in C57Bl/6j mice. Chin Clin Onco 2010;15:689–692.
- Chen Y, Du X, Pei Y. The effects of XiaoAiPing and its combination with Octreotide on hepatocarcinoma H22 on mice. Med Innov China 2011;8:4–6.
- Deng J, Liao Z, Chen D. Marsdenosides A-H, polyoxypregnane glycosides from Marsdenia tenacissima. Phytochemistry 2005;66: 1040–1051.
- Luo SQ, Lin LZ, Cordell GA, et al. Polyoxypregnanes from Marsdenia tenacissima. Phytochemistry 1993;34:1615–1620.
- Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311–322.
- Cory S, Adams JM. The Bcl-2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647–656.
- Chen B, Li C, Chen J, et al. Marsdenia tenacissima extracts inhibited the growth of Jurkat, Raji and RPMI 8226 cell lines. Chin J Biochem Pharm 2009;30:174–177.
- Pickering BM, De Mel S, Lee M, et al. Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 2007;26:1166–1177.
- Li D, Ouyang J, Li C, et al. The effects of Marsdenia tenacissima on the expression of apoptosis genes in U937 cells. Chin J Biochem Pharm 2008;4:240–243.